Invesco Ltd. Raises Stock Holdings in Stoke Therapeutics, Inc. $STOK

Key Points

• Invesco Ltd. increased its stake in Stoke Therapeutics, Inc. by 117.0% in Q1, now owning 26,183 shares worth $174,000.
• Several analysts have rated Stoke Therapeutics as "buy," with target prices ranging from $22.00 to $35.00, reflecting positive market sentiment.
• Stoke Therapeutics reported a quarterly EPS of ($0.40), exceeding estimates, but revenue fell short at $13.82 million compared to expectations of $31.51 million.

Invesco Ltd. grew its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 117.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,183 shares of the company's stock after buying an additional 14,118 shares during the quarter. Invesco Ltd.'s holdings in Stoke Therapeutics were worth $174,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Graham Capital Management L.P. grew its holdings in Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after buying an additional 1,453 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after buying an additional 2,215 shares in the last quarter. Group One Trading LLC grew its holdings in Stoke Therapeutics by 2.8% during the 4th quarter. Group One Trading LLC now owns 104,411 shares of the company's stock valued at $1,152,000 after buying an additional 2,837 shares in the last quarter. California State Teachers Retirement System grew its holdings in Stoke Therapeutics by 16.2% during the 4th quarter. California State Teachers Retirement System now owns 32,068 shares of the company's stock valued at $354,000 after buying an additional 4,468 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on STOK shares. Chardan Capital restated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. HC Wainwright dropped their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 target price for the company. Finally, Wedbush lifted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $25.57.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $21.99 on Tuesday. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $22.39. The firm has a market capitalization of $1.21 billion, a P/E ratio of 25.87 and a beta of 1.14. The stock has a 50 day moving average price of $15.13 and a 200 day moving average price of $11.15.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the sale, the insider directly owned 18,469 shares of the company's stock, valued at $366,979.03. The trade was a 22.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 6,345 shares of Stoke Therapeutics stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total value of $127,344.15. Following the sale, the general counsel directly owned 11,831 shares of the company's stock, valued at approximately $237,448.17. This trade represents a 34.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 107,719 shares of company stock valued at $2,063,359 in the last ninety days. Corporate insiders own 9.50% of the company's stock.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.